Altimmune, Inc. (ALT)
| Market Cap | 501.43M |
| Revenue (ttm) | 6.45M |
| Net Income (ttm) | -42.52M |
| Shares Out | 33.06M |
| EPS (ttm) | -2.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $13.59 |
| Previous Close | $12.93 |
| Change ($) | 0.66 |
| Change (%) | 5.10% |
| Day's Open | 13.24 |
| Day's Range | 12.90 - 13.87 |
| Day's Volume | 1,133,584 |
| 52-Week Range | 1.69 - 33.26 |
New York, New York--(Newsfile Corp. - January 11, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" the "Company") (NASDAQ: ALT). Such invest...
Transport and storage of their potential vaccines would be a piece of cake.
This biotech just might have what it takes.
NEW YORK, Jan. 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" the "Company") (NASDAQ: ALT). Such investors are advised to ...
They're risky but could deliver huge returns in the new year.
Altimmune (ALT) enrolls the first patient in a phase II study evaluating HepTcell for the treatment of patients with chronic hepatitis B. Shares rise.
Altimmune (NASDAQ: ALT) shares were trading higher Wednesday after the company announced it began a multinational Phase 2 clinical trial of HepTcellTM for the treatment of chronic Hepatitis B....
GAITHERSBURG, Md., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first patient in its mu...
It's down, but not out.
Biotechvalley Insights is upgrading ALT's rating to "Very Bullish" from a "Bullish" rating with a 12 month TP of US$52. Altimmune's (ALT) valuation is at a discount after the recent sell-off, ...
Altimmune Inc. (NASDAQ: ALT) shares dropped on Thursday after the company announced that it had received an update from the U.S.
Altimmune, a clinical-stage biopharmaceutical company, fell as much as 10% on Thursday after the FDA issued a clinical hold on the company's COVID-19 vaccine candidate. AdCOVID is a single-dos...
GAITHERSBURG, Md., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)...
Investors are excited about an analyst's bullish opinion about the biotech stock.
GAITHERSBURG, Md., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer of ...
Share price has recently stumbled due to results of the leading vaccines. Vaccine development timeline is way behind the leading vaccines.
Altimmune (ALT) files a regulatory application to begin a phase I study in the United States on AdCOVID, its intranasal COVID-19 vaccine candidate. Stock rises.
Simple, single-dose nasal spray offers greater ease and comfort of administration ; positioning AdCOVID as a differentiated vaccine candidate for adults and children
GAITHERSBURG, Md., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutic...
Altimmune, Inc. (ALT) CEO Vipin Garg on Q3 2020 Results - Earnings Call Transcript
Altimmune Inc. (NASDAQ: ALT) stepped forward on Tuesday with its vaccine candidate for COVID-19.
AdCOVID , a Single-dose Intranasal Vaccine for COVID-19 is Designed to Generate a Broad Immune Response Against COVID-19 with the Unique Ability to Promote Nasal Mucosal Immunity
GAITHERSBURG, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and nine months ...
GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2020 fina...
Altimmune CEO Vipin Garg with the latest on a potential inhaled vaccine
CNBC's Meg Tirrell on coronavirus cases rising. And Vipin Garg, Altimmune CEO, discusses the prospects for his company's inhaled vaccine.
Comprehensive analysis shows AdCOVID uniquely stimulates three key immune compon ents: serum neutralizing antibody , T cell responses , and mucosal immunity in the respiratory tract
In the race for a vaccine, a pause in progress sets you back.
GAITHERSBURG, Md., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following u...
GAITHERSBURG, Md., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Scot Roberts, Ph.D., Chief Scientific Of...
An analyst's buy recommendation fueled investors' enthusiasm about the biotech stock.
Altimmune: The Late Bloomer Of The COVID-19 Biotech World, The Best Is Yet To Come
Each of these biotech stocks has more than tripled year to date and could still have plenty of room to run.
Just follow these three simple steps.
Company anticipates first-in-human trials to start in Q4 2020 Company anticipates first-in-human trials to start in Q4 2020
It's not a surprise that all five of these stocks are engaged in the fight against the novel coronavirus.
Some investors appear to be taking profits off the table with the high-flying biotech stock.
GAITHERSBURG, Md., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced a preclinical data presentation on ALT-801, it...
Antigen-specific CD4+ and CD8+ T cell responses in the lung not previously shown with advanced COVID-19 vaccine candidates Antigen-specific CD4+ and CD8+ T cell responses in the lung not previ...
It’s tough to top quadruple-digit growth.
Altimmune, Inc. (ALT) CEO Vipin Garg on Q2 2020 Results - Earnings Call Transcript
Altimmune earnings from Tuesday evening have ALT stock higher despite the company reporting rough figures for second quarter of FY2020. The post Altimmune Earnings: ALT Stock Rises 7% Despite ...
Shares of Altimmune (NASDAQ:ALT) fell 2.38% in after-market trading after the company reported Q2 results.
GAITHERSBURG, Md., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months...
Altimmune CEO on Covid-19 vaccine and treatment, which involves a nasal spray
Altimmune CEO Vipin Garg discusses the progress of his company's coronavirus vaccine, which is administered through the nasal passages.
GAITHERSBURG, Md., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment in its Phase ...
GAITHERSBURG, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the ...
Here's what drove shares of these healthcare stocks through the roof last month.
GAITHERSBURG, Md., July 22, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company has entered into an agreement...
About ALT
Altimmune, a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVI... [Read more...]
| Industry Biotechnology | |
| CEO Vipin Garg | Employees 25 |
| Stock Exchange NASDAQ | Ticker Symbol ALT |
Financial Performance
In 2019, Altimmune's revenue was $5.80 million, a decrease of -43.85% compared to the previous year's $10.33 million. Losses were -$20.52 million, -47.61% less than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for Altimmune stock is "Strong Buy." The 12-month stock price forecast is 41.40, which is an increase of 204.64% from the latest price.